Edwards Lifesciences (NYSE:EW) VP Sells $818,073.76 in Stock

Edwards Lifesciences Corporation (NYSE:EW) VP Donald Bobo, Jr. sold 9,968 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $82.07, for a total value of $818,073.76. Following the completion of the sale, the vice president directly owned 22,798 shares in the company, valued at approximately $1,871,031.86. This represents a 30.42% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Edwards Lifesciences Stock Up 1.2%

Shares of EW traded up $1.01 during mid-day trading on Monday, reaching $82.39. The company had a trading volume of 4,179,984 shares, compared to its average volume of 4,798,783. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42. The firm has a 50-day moving average price of $81.50 and a 200 day moving average price of $82.87. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $87.89. The company has a market capitalization of $47.44 billion, a price-to-earnings ratio of 43.82, a price-to-earnings-growth ratio of 2.04 and a beta of 0.87.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The firm had revenue of $1.65 billion for the quarter, compared to analysts’ expectations of $1.60 billion. During the same period in the previous year, the firm posted $0.64 EPS. The business’s revenue for the quarter was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, sell-side analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on EW shares. Barclays reaffirmed an “overweight” rating and issued a $110.00 price objective (up from $104.00) on shares of Edwards Lifesciences in a research report on Monday, April 27th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Monday, April 20th. Canaccord Genuity Group set a $85.00 price objective on Edwards Lifesciences and gave the company a “hold” rating in a research report on Friday, April 24th. Wolfe Research raised Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price objective on the stock in a research report on Wednesday, April 1st. Finally, Mizuho set a $95.00 price objective on Edwards Lifesciences and gave the company an “outperform” rating in a research report on Monday, April 13th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, Edwards Lifesciences has an average rating of “Moderate Buy” and an average target price of $95.65.

Institutional Investors Weigh In On Edwards Lifesciences

Hedge funds have recently added to or reduced their stakes in the stock. MV Capital Management Inc. purchased a new stake in Edwards Lifesciences during the 4th quarter valued at $26,000. Hanson & Doremus Investment Management purchased a new stake in Edwards Lifesciences during the 1st quarter valued at $25,000. Kemnay Advisory Services Inc. purchased a new stake in Edwards Lifesciences during the 4th quarter valued at $27,000. JPL Wealth Management LLC purchased a new stake in Edwards Lifesciences during the 3rd quarter valued at $25,000. Finally, Hilton Head Capital Partners LLC purchased a new stake in Edwards Lifesciences during the 4th quarter valued at $28,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.